Pharmacotherapy with oral Xa inhibitors for venous thromboembolism

Bibliography

• Kearon C. Natural history of venous thromboembolism. Circulation 2003;107(23 Suppl 1):I22-30
   PubMed Web of Science ®Google Scholar
• Martinelli I, Franchini M, Mannucci PM. How I treat rare venous thromboses. Blood 2008;112(13):4818-23
   Google Scholar
• White RH. The epidemiology of venous thromboembolism. Circulation 2003;107(23 Suppl 1):I4-8
   PubMed Web of Science ®Google Scholar
• Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl):381S-453S
   PubMed Web of Science ®Google Scholar
• Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007;98(4):756-64
   PubMed Web of Science ®Google Scholar
• Murray GD, Best CH. The use of heparin in thrombosis. Ann Surg 1938;108(2):163-77
   PubMedGoogle Scholar
• Schulman S. Treatment of venous thromboembolism with dabigatran. Curr Opin Pulm Med 2012;18(5):410-15
   Google Scholar
• EINSTEIN Investigators. Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363(26):2499-510
   PubMed Web of Science ®Google Scholar
• EINSTEIN-PE Investigators. Buller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366(14):1287-97
   PubMed Web of Science ®Google Scholar
• Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369(9):799-808
   PubMed Web of Science ®Google Scholar
• Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013;368(8):699-708
   PubMed Web of Science ®Google Scholar
• Hokusai VTEI, Buller HR, Decousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013;369(15):1406-15
   PubMed Web of Science ®Google Scholar
• Buller HR, Halperin JL, Bounameaux H, Prins M. Double-blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants. J Thromb Haemost 2008;6(2):227-9
   PubMed Web of Science ®Google Scholar
• Casteels M, Flamion B. Open-label trials and drug registration: a European regulator’s view. J Thromb Haemost 2008;6(2):232-4
   Google Scholar
• Brandjes DP, Heijboer H, Buller HR, et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992;327(21):1485-9
   PubMed Web of Science ®Google Scholar
• van Gogh I, Buller HR, Cohen AT, et al. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007;357(11):1094-104
   PubMed Web of Science ®Google Scholar
• Schulman S, Wahlander K, Lundstrom T, et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003;349(18):1713-21
   PubMed Web of Science ®Google Scholar
• van Es N, Coppens M, Schulman S, et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014;124(12):1968-75
   PubMed Web of Science ®Google Scholar
• Greenberg PD, Cello JP, Rockey DC. Relationship of low-dose aspirin to GI injury and occult bleeding: a pilot study. Gastrointest Endosc 1999;50(5):618-22
   Google Scholar
• Geldhof V, Vandenbriele C, Verhamme P, Vanassche T. Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants. Thromb J 2014;12:21
   Google Scholar
• Bristol-Myers Squibb, Pfizer EEIG. Eliquis® (apixaban) Summary of Product Characteristics. 2011. Available from: http://www.medicines.org.uk/EMC/medicine/24988
   Google Scholar
• Bayer Pharma AG. Xarelto® (rivaroxaban) Summary of Product Characteristics. 2012. Available from: http://www.xarelto.com/html/downloads/Xarelto-prescribing_information-nov-2012.pdf
   Google Scholar
• Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e691S-736S
   PubMed Web of Science ®Google Scholar
• Lyman GH. Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer 2011;117(7):1334-49
   PubMed Web of Science ®Google Scholar
• Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(2 Suppl):e419S-94S
   PubMed Web of Science ®Google Scholar
• Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(2 Suppl):e227S-77S
   PubMed Web of Science ®Google Scholar
• Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e195S-226S
   PubMed Web of Science ®Google Scholar
• Vedovati MC, Germini F, Agnelli G, Becattini C. Direct oral anticoagulants in patients with venous thromboembolism and cancer: a systematic review and meta-analysis. Chest 2014. [ Epub ahead of print]
   Google Scholar
• van der Hulle T, Huisman MV, Klok FA. Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism: reply. J Thromb Haemost 2014. [ Epub ahead of print]
   Google Scholar
• Carrier M, Cameron C, Delluc A, et al. Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. Thromb Res 2014;134(6):1214-19
   PubMed Web of Science ®Google Scholar
• Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009;374(9683):29-38
   PubMed Web of Science ®Google Scholar
• Authors/Task Force Members. Konstantinides SV, Torbicki A, et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Endorsed by the European Respiratory Society (ERS). Eur Heart J 2014;35(43):3033-73
   Google Scholar
• Kearon C. Influence of hereditary or acquired thrombophilias on the treatment of venous thromboembolism. Curr Opin Hematol 2012;19(5):363-70
   Google Scholar
• Linkins LA, Warkentin TE, Pai M, et al. Design of the rivaroxaban for heparin-induced thrombocytopenia study. J Thromb Thrombolysis 2014;38(4):485-92
   PubMed Web of Science ®Google Scholar
• Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15(5):625-51
   PubMed Web of Science ®Google Scholar